Statins Can Delay Insulin Use and Reduce Diabetes-related Diseases in Asian Patients With Type 2 Diabetes

Hsin-Hung Chen, Chi-Hung Yeh, Cheng-Li Lin, Su-Yin Yeh, and Chia-Hung Kao

Abstract: We evaluated the role of statins in delaying insulin use and diabetes-related diseases in Asian patients with type 2 diabetes mellitus (T2DM) because statins can cause new-onset diabetes.

We used data from the Longitudinal Health Insurance Database in this retrospective cohort study. The 12,470 T2DM patients were categorized into two cohorts: a statin cohort comprising 2,545 patients who received statin therapy for at least 6 months (180 days) before the index date and a nonstatin cohort comprising 9,925 patients who did not receive statin therapy. The control-to-case ratio was set at approximately 4:1. Univariable and multivariable Cox proportional hazards regression analyses were performed to evaluate the risk of diabetes-related events and insulin use on receiving statin treatment.

Patients in the statin cohort had a 48% lower risk of diabetes-related coma than those in the nonstatin cohort (95% confidence interval = 0.29–0.92). Patients with >730 days of statin therapy had a significantly lower risk of insulin use, diabetes-related disorders of the eye and neurons, and peripheral circulatory disorders. Compared with patients in the nonstatin cohort, the risk of insulin use, diabetes-related coma, and diabetes-related disorders of the eye and neurons was lower in patients on a cumulative defined daily dose (cDDD) of statins for >475 days.

These results suggest that longer duration of statin use and higher cDDD of statins can delay insulin use in Asian patients with T2DM.

INTRODUCTION

S

tatins, or hydroxymethylglutaryl-coenzyme-A (HMG-CoA) reductase inhibitors, are a medication widely prescribed worldwide to reduce hyperlipidemia-related atherosclerotic complications such as stroke or acute myocardial infarction. Statins not only reduce hyperlipidemia but also attenuate expression of inflammatory markers such as C-reactive protein. UK Prospective Diabetes Study 23 (UKPDS 23) reported that low-density lipoprotein cholesterol (LDL-C) is the strongest predictor of the risk of coronary heart disease (CHD) in patients with diabetes. Five major contributors to CHD risk, namely, LDL-C, HDL-C, hemoglobin A1c (HbA1c), systolic blood pressure, and smoking, were mentioned in UKPDS 23, and the data in this study support the need for reducing LDL-C levels to reduce CHD risk in patients with type 2 diabetes mellitus (T2DM). In addition, the Multiple Risk Factor Intervention Trial showed that total cholesterol, smoking, and blood pressure can predict the occurrence of cardiovascular diseases in diabetic and nondiabetic patients. On the basis of these findings and according to the guidelines of the American Diabetes Association, statines have always been the preferred first-line medication for diabetic patients with hyperlipidemia. However, the Food and Drug Administration in the United States suggests that statin therapy can increase HbA1c and fasting blood glucose levels. The associations between statin therapy and new-onset diabetes have been widely discussed recently. Further analysis of previous clinical trials suggests that patients with T2DM risk factors are at a high new-onset diabetes risk after statin use. We investigated the role of statin therapy in improving glycemic control or reducing T2DM-related complications in patients. One of the reasons for providing insulin therapy to patients with T2DM is that T2DM is a progressive disease with β-cell failure. Our hypothesis is that statins can delay insulin use in patients with T2DM, and if proven, it may act as direct or indirect evidence to confirm that although statins can cause new-onset diabetes, they may be used for diabetic control.

doi:10.1097/MD.0000000000000735
METHODS

Data Source

National Health Insurance (NHI) is a single-payer mandatory insurance program that was implemented in Taiwan in 1995 and covers all forms of health care for the residents of Taiwan (http://www.nhi.gov.tw/english/index.aspx). NHI covers outpatient, inpatient, emergency, dental, and traditional Chinese medicine services, as well as prescription drugs. This retrospective cohort study used data from the Longitudinal Health Insurance Database (LHID), a subset of the National Health Insurance Research Database (NHIRD), which was released by the Taiwan Bureau of National Health Insurance. The LHID was constructed in 2000 by randomly selecting 1,000,000 enrollees from the Registry for Beneficiaries of the NHI program. No significant differences were observed in distributions of sex, age, and health costs between patients in the LHID and in the NHRI (http://nhird.nhri.org.tw/en/Data-Subsets.html#S3). The patients were identified and diagnosed on the basis of International Classification of Disease, Ninth Revision, Clinical Modification (ICD-9-CM) codes. This study was exempted by the Institutional Review Board of China Medical University in Central Taiwan (CMU-REC-101–012).

Sampled Participants

Patients aged 20 years or older and diagnosed with T2DM from 2000 to 2010 were selected from the LHID for this study. The retrospective cohort comprised 12,470 T2DM patients. The index date was defined as the date of T2DM diagnosis. Patients were categorized into 2 cohorts: a statin cohort comprising 2545 patients who received statin therapy for at least 6 months (180 days) before the index date and a nonstatin cohort comprising 9925 patients who did not receive any statin therapy. The controls in the nonstatin cohort were randomly assigned the same index date as the patients in the statin cohort. The patients in the nonstatin cohort were frequency-matched for age (in 5-year bands), sex, the year of statin use, and the index year of T2DM diagnosis. The control-to-case ratio was set at approximately 4:1 to enhance the power of statistical tests. Patients in both cohorts with a history of diabetes-related eye disorders (ICD-9-CM 250.5), diabetes-related peripheral circulatory disorders (PCDs) (ICD-9-CM 250.7), diabetes-related ketoacidosis (ICD-9-CM 250.1), diabetes-related renal manifestations (ICD-9-CM 250.4), diabetes-related coma (ICD-9-CM 205.2 and 250.3), and diabetes-related neurological disorders (ICD-9-CM 250.61 and 250.63); patients with insulin use before the index date; patients aged younger than 20 years; and patients with incomplete information were excluded.

Measurement of Outcomes

The study events included diabetes-related disorders of the eye and neurons, diabetes-related PCD, diabetes-related ketoacidosis, diabetes-related renal manifestations, diabetes-related coma, and insulin use. All patients were followed-up from the index date to the event occurrence date, withdrawal from the NHII system, or the end of the follow-up period (December 31, 2011).

Variables of Interest

The potential comorbidities and medications for diabetes-related events included coronary artery disease (ICD-9-CM 410–414), hypertension (ICD-9-CM 401–405), hyperlipidemia (ICD-9-CM 272), and chronic kidney disease (ICD-9-CM 585) and thiazolidinediones, sulfonylurea, and metformin. All comorbidities and medications were defined before the index date.

Statistical Analysis

The $\chi^2$ and Student t tests were used to assess the differences for the categorical and continuous variables between the statin and nonstatin cohorts. The incidence (per 1000 person-y) of diabetes-related events and insulin use was calculated for both cohorts. Univariable and multivariable Cox proportional hazards regression analyses were performed to estimate the risk of diabetes-related events and insulin use on receiving statin treatment. Hazard ratios (HRs) and 95% confidence intervals (CIs) were provided in the Cox models. The multivariable models were adjusted for factors such as age; sex; comorbidities such as coronary artery disease, hypertension, hyperlipidemia, and chronic kidney disease; and medications such as thiazolidinediones, sulfonylurea, and metformin, which differed significantly between the 2 groups, as listed in Table 1. The defined daily dose, recommended by the World Health Organization, is the assumed average maintenance dose per day of a drug. We calculated the cumulative defined daily dose (cDDD) was calculated the total prescribed defined daily dose of each type of statin for statin users. In addition, we evaluated the effect of statin use duration ($\leq 365$, $365–730$, and $>730$ days) and cDDD ($\leq 265$, $266–475$, and $>475$ days) for the risk of diabetes-related events and insulin use. We used SAS software (Version 9.3 for Windows; SAS Institute Inc, Cary, NC) for all data analyses. A 2-tailed $P$ value of $<0.05$ was considered statistically significant.

| TABLE 1. Comparisons in Demographic Characteristics and Comorbidities in Type 2 Diabetes Mellitus Patient With and Without Statin |
|---------------------------------------------------------------|
| **Statin** | **No** (N = 9925) | **Yes** (N = 2545) | **P** |
| **Sex** | | | |
| Women | 5404 (54.5) | 1404 (55.2) | 0.52 |
| Men | 4521 (45.6) | 1141 (44.8) | |
| **Age stratified** | | | 0.51 |
| ≤ 49 | 1500 (15.1) | 375 (14.7) | |
| 50–64 | 4575 (46.1) | 1151 (45.2) | |
| >65+ | 3850 (38.8) | 1019 (40.0) | |
| **Age, mean±SD** | | | 0.19 |
| Comorbidity | 61.4 (11.1) | 61.7 (11.1) | |<0.001 |
| Coronary artery disease | 2676 (27.0) | 1204 (47.3) | |
| Hypertension | 6111 (61.6) | 2167 (85.2) | |<0.001 |
| Hyperlipidemia | 4113 (41.4) | 2406 (94.5) | |<0.001 |
| Chronic kidney disease | 137 (1.38) | 74 (2.91) | |<0.001 |
| Medication | | | |
| Thiazolidinediones | 57 (0.57) | 65 (2.55) | |<0.001 |
| Sulfonylurea | 2397 (24.2) | 553 (21.7) | 0.01 |
| Metformin | 2760 (27.8) | 804 (31.6) | |<0.001 |

Chi-Square Test. * t Test.
RESULTS

Most participants were women and 50 to 64 years’ old. The mean ages of patients in the statin and nonstatin cohorts were 61.7 (SD = 11.1) and 61.4 (SD = 11.1) years, respectively.

Patients in the statin cohort were more likely to have coronary artery disease, hypertension, hyperlipidemia, and chronic kidney disease than those in the nonstatin cohort (P < 0.001). Thiazolidinediones and metformin medication were more prevalent in the statin cohort at the baseline (P < 0.001) compared with the nonstatin cohort.

Table 2 shows the incidence rates of diabetes-related events and insulin use for both cohorts and the HR of the statin to the nonstatin cohorts. The statin cohort (1.46 per 1000 person-years) had a lower incidence of diabetes-related coma than the nonstatin cohort (2.84 per 1000 person-years). Patients in the statin cohort had a 48% lower risk of diabetes-related coma than those in the nonstatin cohort (95% confidence interval = 0.29–0.92). The associations between the duration of statin use and the risk of diabetes-related events and insulin use are shown in Table 3. Patient with ≤365 days of statin therapy were at significantly higher risks of diabetes-related renal manifestations, diabetes-related disorders of the eye and neurons, and insulin use compared with patients in the nonstatin cohort. Patients with >730 days of statin therapy had significantly lower risks of diabetes-related disorders of the eye and neurons, diabetes-related peripheral circulatory disorders, and insulin use than those in the nonstatin cohort.

Furthermore, based on estimation of the risk of diabetes-related events and insulin use on the basis of cDDD for statin, the patients with statin therapy exhibited an association with diabetes-related events and insulin use (Table 4). Patients receiving ≤265 cDDD of statin therapy had significantly higher risks of diabetes-related renal manifestations, diabetes-related eye disorders, and insulin use than those in the nonstatin cohort.

The risk of diabetes-related coma, diabetes-related eye disorders of the eye and neurons, and insulin use was lower in patients who received >475 cDDD of statin therapy than those in the nonstatin cohort.

DISCUSSION

Statin, New-onset Diabetes, and T2DM Control

According to the West of Scotland Coronary Prevention Study, a protective effect of pravastatin can prevent new-onset diabetes. However, other statins, such as atorvastatins, rosuvastatins, and simvastatins, can increase the fasting blood glucose and HbA1c levels. In our study, as shown in Table 2, fewer diabetic patients used insulin to control T2DM in the statin cohort, although the crude HR was significant instead of the adjusted HR. As shown in Table 3, >730 days instead of 365 days of statin therapy can substantially reduce insulin use in diabetic patients. In addition, previous studies on statins, such as the Study of Heart and Renal Protection for simvastatin and the Lescol Intervention Prevention Study for fluvastatin, have reported that the beneficial duration of statin use was >1 year. Moreover, statin use for >475 cDDD can reduce insulin use in diabetic patients. Our finding differs from that of a previous study that suggested that intensive-dose statin therapy compared with moderate-dose statin therapy increases new-onset diabetes.

Statins and Insulin

Simvastatin and atorvastatin are lipophilic statins. These statins have been reported to reduce insulin secretion. One possible mechanism is the inhibition of glucose-stimulated elevations of free calcium in pancreatic β-cells. High-dose statin therapy with simvastatin significantly reduces insulin secretion; however, these studies could not explain our

| TABLE 2. Comparison of Incidence Densities of Diabetes-related Events and Insulin Use Hazard Ratio Between Type 2 Diabetes Mellitus Patient With and Without Statin |
|-----------------|----------------|----------------|
| Statin          | No             | Yes            |
| Event PY Rate  | Event PY Rate  | Crude HR (95% CI) | Adjusted HR (95% CI) |
| Diabetes-related diseases |        |               |                  |                  |
| Ketoacidosis    | 71 41295       | 15 10920       | 0.80 (0.46, 1.39) | 0.76 (0.41, 1.41) |
| Coma            | 17 41266       | 16 10931       | 0.52 (0.31, 0.87)*| 0.52 (0.29, 0.92)*|
| Renal manifestations | 731 39702 | 231 10434 | 1.20 (1.04, 1.39)*| 1.09 (0.92, 1.29)*|
| Eye involvement | 364 40620 | 110 10652 | 1.15 (0.93, 1.42) | 1.11 (0.87, 1.42) |
| Neurological    | 624 39528 | 152 10499 | 1.02 (0.77, 1.10) | 0.86 (0.71, 1.16) |
| PCD             | 322 40553 | 74 671 | 0.79 (0.60, 1.02) | 0.83 (0.61, 1.11) |
| Medication      |               |               |                  |                  |
| Insulin use     | 4622 30948 | 149 113 | 0.92 (0.86, 0.98)**| 0.94 (0.87, 1.01)**|

CI = confidence interval, HR = relative hazard ratio, PCD = peripheral circulatory disorder, PY = person-years.

* P < 0.05.
** P < 0.01.
*** P < 0.001.

Rate, incidence rate, per 1000 person-years.

§ Crude HR: The relative hazard ratio without adjustment for age, sex, and co-morbidities of coronary artery disease, hypertension, hyperlipidemia, and chronic kidney disease and medication of thiazolidinediones, sulfonylurea, and metformin by univariable Cox proportional hazards regression.

† Adjusted HR: The relative hazard ratio with adjustment for age, sex, co-morbidities and medication by multivariable Cox proportional hazards regression.
findings. Statins can reduce isoprenoids produced in the cholesterol synthetic pathway. Isoprenoids can upregulate the insulin-responsive glucose transporter (GLUT)-4 expression, and this protein enhances glucose uptake.20 Lovastatin can reduce insulin sensitivity through downregulation of GLUT-4 and upregulation of GLUT-1 in 3T3-L1 adipocytes.21 A decrease in the availability of isoprenoids or adiponectin after statin use could result in insulin resistance, and finally, it may worsen glycemic control in diabetic patients. However, certain studies have reported that statins could reduce insulin resistance22 or stimulate adiponectin secretion.23 We adjusted for metformin and thiazolidinedione medication in our analysis, which were confounders for insulin resistance. Significant adjusted HRs showed that statins can delay insulin use in diabetic patients.

### TABLE 3. Incidence and Adjusted Hazard Ratio of Diabetes-related Events and Insulin Use Stratified by Duration of Statin Use

| Statin exposed | N     | Event | Rate | Crude HR (95% CI) | Adjusted HR (99.5% CI) |
|----------------|-------|-------|------|-------------------|------------------------|
| Diabetes-related ketoacidosis |       |       |      |                   |                        |
| No use         | 9925  | 71    | 1.72 | 1.00              | 1.00                   |
| ≤365 days      | 344   | 5     | 0.87 | 1.64 (0.60, 4.49) | 1.38 (0.49, 3.91)      |
| 366–730 days   | 1093  | 4     | 1.21 | 0.90 (0.41, 1.95) | 0.82 (0.36, 1.85)      |
| >730 days      | 1108  | 6     | 3.19 | 0.47 (0.17, 1.28) | 0.46 (0.16, 1.31)      |
| Diabetes-related coma |     |       |      |                   |                        |
| No use         | 9925  | 117   | 2.84 | 1.00              | 1.00                   |
| ≤365 days      | 344   | 2     | 0.35 | 0.75 (0.24, 2.35) | 0.69 (0.21, 2.23)      |
| 366–730 days   | 1093  | 8     | 2.42 | 0.54 (0.25, 1.17) | 0.56 (0.25, 1.23)      |
| >730 days      | 1108  | 6     | 3.18 | 0.42 (0.19, 0.96) | 0.43 (0.18, 1.01)      |
| Diabetes-related renal manifestations |     |       |      |                   |                        |
| No use         | 9925  | 731   | 18.4 | 1.00              | 1.00                   |
| ≤365 days      | 344   | 79    | 14.2 | 1.69 (1.23, 2.32) | 1.43 (1.03, 1.98)      |
| 366–730 days   | 1093  | 64    | 20.1 | 1.33 (1.08, 1.63) | 1.18 (0.95, 1.48)      |
| >730 days      | 1108  | 52    | 52.8 | 0.96 (0.77, 1.20) | 0.89 (0.70, 1.13)      |
| Diabetes-related eye involvement |     |       |      |                   |                        |
| No use         | 9925  | 364   | 8.96 | 1.00              | 1.00                   |
| ≤365 days      | 344   | 39    | 6.90 | 1.96 (1.29, 2.96) | 1.74 (1.14, 2.69)      |
| 366–730 days   | 1093  | 27    | 8.34 | 1.48 (1.12, 1.95) | 1.42 (1.05, 1.92)      |
| >730 days      | 1108  | 44    | 24.9 | 0.64 (0.43, 0.93) | 0.62 (0.42, 0.93)      |
| Diabetes-related neurological |     |       |      |                   |                        |
| No use         | 9925  | 322   | 7.94 | 1.00              | 1.00                   |
| ≤365 days      | 344   | 22    | 3.87 | 1.72 (1.22, 2.41) | 1.51 (1.06, 2.15)      |
| 366–730 days   | 1093  | 14    | 4.27 | 1.15 (0.91, 1.45) | 1.06 (0.83, 1.37)      |
| >730 days      | 1108  | 31    | 17.0 | 0.51 (0.37, 0.70) | 0.49 (0.35, 0.68)      |
| Diabetes-related PCD |    |       |      |                   |                        |
| No use         | 9925  | 624   | 15.8 | 1.00              | 1.00                   |
| ≤365 days      | 344   | 55    | 9.85 | 0.99 (0.54, 1.80) | 0.99 (0.53, 1.82)      |
| 366–730 days   | 1093  | 49    | 15.4 | 1.08 (0.77, 1.51) | 1.12 (0.78, 1.62)      |
| >730 days      | 1108  | 48    | 27.7 | 0.46 (0.29, 0.74) | 0.49 (0.30, 0.81)      |
| Insulin use    |       |       |      |                   |                        |
| No use         | 9925  | 4622  | 149.3| 1.00              | 1.00                   |
| ≤365 days      | 344   | 414   | 84.5 | 1.55 (1.35, 1.79) | 1.45 (1.25, 1.68)      |
| 366–730 days   | 1093  | 326   | 126.3| 1.13 (1.04, 1.24) | 1.16 (1.05, 1.27)      |
| >730 days      | 1108  | 400   | 458.8| 0.63 (0.57, 0.70) | 0.65 (0.58, 0.72)      |

CI = confidence interval, HR = relative hazard ratio, PCD = peripheral circulatory disorder.

*P < 0.05.
**P < 0.01.
***P < 0.001.
\(^{1}\) Rate, incidence rate, per 1000 person-years.
\(^{1}\) Crude HR: The relative hazard ratio without adjustment for age, sex, and co-morbidities of coronary artery disease, hypertension, hyperlipidemia, and chronic kidney disease and medication of thiazolidinediones, sulfonylurea, and metformin by univariable Cox proportional hazards regression.
\(^{1}\) Adjusted HR: The relative hazard ratio with adjustment for age, sex, co-morbidities, and medication by multivariable Cox proportional hazards regression.
Statins and Diabetes-related Diseases

In the Scandinavian Simvastatin Survival Study, simvastatin significantly reduced CHD incidence and total mortality in diabetic patients with high LDLC levels. Our analysis showed that longer duration of statin use and higher cDDD of statin therapy can reduce diabetes-related diseases such as coma, renal manifestations, eye disorders, and PCD. From our analyses of diabetes-related ketoacidosis and coma, we infer that statin therapy can be used for diabetic control in Asian patients.

CONCLUSION

In our study, longer duration and higher cDDD of statin therapy can delay insulin use and reduce diabetes-related diseases in diabetic patients.
Limitations
First, additional data such as drinking, smoking, body mass index, nutritional state, or red rice use are unavailable in the NHIRD, and therefore unknown confounders may have affected the results of this study. Second, to understand the association between insulin and statins in patients with T2DM, we could use only the cDDD of statins for our analysis.

REFERENCES
1. Mills E, Wu P, Chong G, et al. Efficacy and safety of statin treatment for cardiovascular disease: a network meta-analysis of 170 255 patients from 76 randomized trials. QJM. 2011;104:109–124.
2. Kearney PM, Blackwell L, Collins R, et al. Efficacy of cholesterollowering therapy in 18, 686 people with diabetes in 14 randomised trials of statins: a metaanalysis. Lancet. 2008;371:117–125.
3. Baigent C, Blackwell L, Emberson J, et al. Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170 000 participants in 26 randomised trials. Lancet. 2010;376:1670–1681.
4. Ridker PM, Danielson E, Fonseca FAH, et al. Reduction in C-reactive protein and LDL cholesterol and cardiovascular event rates after initiation of rosuvastatin: a prospective study of the JUPITER trial. Lancet. 2009;373:1175–1182.
5. Turner RC, Mills H, Neil HA, et al. Risk factors for coronary artery disease in non-insulindependent diabetes mellitus: United Kingdom prospective diabetes study (UKPDS. 23). BMJ. 1999;316:822–828.
6. Savage PJ. Cardiovascular complications of diabetes mellitus: what we know and what we need to know about their prevention. Ann Intern Med. 1996;124:123–126.
7. FDA Drug Safety Communication: Important Safety Label Changes to Cholesterol-Lowering Statin Drugs. Available at: http://www.fda.gov/Drugs/DrugSafety/ucm293101.htm. Accessed February 28, 2012.
8. Sattar N, Preiss D, Murray HM, et al. Statins and risk of incident diabetes: a collaborative meta-analysis of randomised statin trials. Lancet. 2011;377:2181–2192.
9. Williams AJ, Long AE. Following the fate of the failing (-cell: new insights from first-phase insulin responses. Diabetes. 2013;62:3990–3992.
10. Wasser DD, Ho JE, Boekholdt SM, et al. Cardiovascular event reduction versus new-onset diabetes during atorvastatin therapy: effect of baseline risk factors for diabetes. J Am Coll Cardiol. 2013;61:148–152.
11. Koh K, Quon M, Han S, et al. Simvastatin improves the flow mediated dilation, but reduces adiponectin levels and insulin sensitivity in hypercholesterolemic patients. Diabetes Care. 2008;31:776–782.
12. Koh K, Quon M, Han S, et al. Simvastatin improves the flow mediated dilation, but reduces adiponectin levels and insulin sensitivity in hypercholesterolemic patients. Diabetes Care. 2008;31:776–782.
13. Koh K, Quon M, Han S, et al. Simvastatin improves the flow mediated dilation, but reduces adiponectin levels and insulin sensitivity in hypercholesterolemic patients. Diabetes Care. 2008;31:776–782.
14. Koh K, Quon M, Han S, et al. Simvastatin improves the flow mediated dilation, but reduces adiponectin levels and insulin sensitivity in hypercholesterolemic patients. Diabetes Care. 2008;31:776–782.